Portal de investigación
DETECCIÓN DE LA MUTACIÓN T790M MEDIANTE TECNOLOGÍA BEAMING EN PACIENTES CON CPCNP Y EGFR MUTADO EN ESTADIO IV.
Datos básicos
- Código:
- SYS-ONC-2015-001
- Protocolo:
- SYS-ONC-2015-001
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2015
- Año de finalización:
Objetivos del proyecto
Observaciones: Estado Comité: ACTIVO
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.
Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro
Article. 10.1080/17474086.2024.2313457. 2024
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
Provencio-Pulla, Mariano; (...); Rueda, Antonio
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7550. 2018
A consensus statement on the gender perspective in lung cancer
Isla, D; (...); de Castro, J
Review. 10.1007/s12094-016-1578-x. 2017
A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; (...); Gumà J
Article. 10.3390/cancers16051034. 2024
A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 2021
A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors
Gonzalez-Cao, M; (...); Rosell, R
Meeting Abstract. 2017
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Camidge DR; (...); Smit E
Article. 10.1016/j.cllc.2022.03.003. 2022
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
Juan, O, Popat, S
Review. 10.1016/j.cllc.2017.03.002. 2017
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)
Morgensztern, D; (...); ABOUND 2L Investigators
Article. 10.1002/cncr.31779. 2018
Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
Romero, A; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2019.08.1463. 2019
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro, A; (...); Cho, B C
Article. 10.1016/j.annonc.2023.10.117. 2024
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
Diaz-Beveridge, R; (...); Aparicio, J
Article. 10.1007/s12094-017-1720-4. 2018
An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.
Dowlati, Afshin; (...); Carpeno, Javier de Castro
Meeting Abstract. 2022
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A; (...); Oramas J
Article. 10.21037/tlcr-21-559. 2021
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Conde, E; (...); Lopez-Rios, F
Article. 10.1016/j.jtho.2019.07.005. 2019
Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer
Garrido, P; (...); Vinolas, N
Meeting Abstract. 10.1016/j.jtho.2019.08.685. 2019
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection The Phase 2 DURVAST Study
Gonzalez-Cao, M; (...); Rosell, R
Article. 10.1001/jamaoncol.2020.0465. 2020
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.
Vicente-Baz D; (...); Provencio M
Article. 10.1016/j.patol.2019.11.002. 2020
ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
Baz, DV; (...); Pulla, MP
Meeting Abstract. 10.1016/S1556-0864(18)30430-1. 2018
ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
Nadal, E; (...); Bruna, J
Meeting Abstract. 10.1016/j.jtho.2019.08.826. 2019
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
Andric, Zoran; (...); Ciardiello, Fortunato
Article. 10.1016/j.jtocrr.2022.100461. 2023
Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Garcia-Sanchez, J.; (...); Lahoz, A.
Meeting Abstract. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Vidal, O. J. Juan; (...); Wolf, J.
Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L; (...); de la Cruz-Merino L
Article. 10.3389/fimmu.2024.1293931. 2024
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Jimenez-Cortegana, C; (...); de la Cruz-Merino, L
Article. 10.1136/jitc-2020-002323. 2021
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, T; (...); Torres, JMS
Article. 10.1016/j.cllc.2020.04.011. 2020
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Rodriguez-Pinilla SM; (...); Cordoba, Raul
Article. 10.1111/bjh.16741. 2021
Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)
Franco, FF; (...); Provencio, M
Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021
Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia, Jon; (...); Paz-Ares, Luis G.
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.9101. 2018
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Zugazagoitia, J; (...); Garrido, P
Article. 10.1016/j.lungcan.2019.05.032. 2019
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia, J; (...); Paz-Ares, L
Article. 10.1093/annonc/mdy512. 2019
Clinical Utility of Plasma-Based NGS for AdvancedStage NSCLC Patients with Insufficient or Unavailable Tumor Tissue
Zugazagoitia, J.; (...); Garrido, P.
Meeting Abstract. 2017
Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.
Romero, Atocha; (...); Provencio-Pulla, Mariano
Meeting Abstract. 2020
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.
Romero A; (...); Provencio M
Article. 10.1002/1878-0261.12832. 2020
Comprehensive genomic profile by Foundation Medicine test in guiding routine decisions for secondline treatment in advanced non-small cell breast cancer (NSCLC): Preliminary results of lung-ONE study.
Rojo, Federico; (...); De Castro, Javier
Meeting Abstract. 2020
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
Provencio, M; (...); Rueda, A
Letter. 10.1080/10428194.2018.1509322. 2019
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
García-Campelo R; (...); Dómine M
Correction. 10.1007/s12094-023-03290-7. 2023
Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.
Pardo-Sanchez, Jose Miguel; (...); Farràs R
Article. 10.3390/cancers13194825. 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].
Reck, M.; (...); John, T.
Correction. 10.1016/j.esmoop.2021.100345. 2021
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.
Isla, D; (...); Rubio-Rodriguez, D
Article. 10.2147/CEOR.S121093. 2017
Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients
Juan, O, Popat, S
Editorial Material. 10.1016/j.lungcan.2016.11.007. 2017
Current treatment landscape for oligometastatic non-small cell lung cancer
Garde-Noguera, Javier; (...); Counago, Felipe
Article. 10.5306/wjco.v13.i6.485. 2022
CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.
Becker JH; (...); Shimamura T
Article. 10.1158/0008-5472.CAN-19-0024. 2019
Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Aransay, N. Reguart; (...); Vila, A. Lloansi
Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023
Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Becker, J; (...); Shimamura, T
Meeting Abstract. 10.1016/j.jtho.2019.08.1478. 2019
Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Suay, G.; (...); Juan-Vidal, O.
Meeting Abstract. 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn, Myung-Ju; (...); Sands, Jacob
Article. 10.1200/JCO-24-01544. 2024
Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01
Sands, J.; (...); Ahn, M-J
Meeting Abstract. 2024
Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)
Franco, F; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1694. 2020
Determination of essential biomarkers in lung cancer: A real-world data study in Spain
Calvo de Juan, V.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2022.02.048. 2022
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
Provencio, Mariano; (...); Torrente, Maria
Article. 10.1186/s12885-022-09830-8. 2022
Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study
Vidal, O. J. Juan; (...); Martinez, B. Valdivieso
Meeting Abstract. 2023
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study
Reinmuth, Niels; (...); Bondarenko, Igor
Meeting Abstract. 2022
Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations
Salvador Coloma, C.; (...); Juan, O.
Meeting Abstract. 10.1016/S1556-0864(16)30269-6. 2016
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Salvador-Coloma, C; (...); Juan, O
Article. 10.21037/jtd.2018.02.30. 2018
ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.
Meeting Abstract. 2023
ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY
de Castro, J; (...); Rojo, F
Meeting Abstract. 2020
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
Angelats, L; (...); Costa, EC
Meeting Abstract. 2019
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta
Meeting Abstract. 2024
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
Reck, M; (...); Spigel, DR
Meeting Abstract. 2018
Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Morgensztern, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.626. 2018
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
Remon, J; (...); Felip, E
Article. 10.1007/s12094-017-1700-8. 2017
Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin Et Chemo-Radiation in Stage III NSCLC. SLCG 10/02
Isla, D; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2016.11.421. 2017
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma
Pulido, I; (...); Shimamura, T
Article. 10.1158/0008-5472.CAN-20-0141. 2020
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Franco, F; (...); Provencio, M
Article. 10.1371/journal.pone.0251761. 2021
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell, R; (...); BELIEF collaborative group
Article. 10.1016/S2213-2600(17)30129-7. 2017
European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.
Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar
Article. 10.21037/cco-23-100. 2024
Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Conde, E; (...); Lopez-Rios, F
Meeting Abstract. 10.1016/j.jtho.2018.08.785. 2018
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Arriola E; (...); Felip E
Article. 10.1007/s40261-024-01379-7. 2024
Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
Cao, MG; (...); Costa, RR
Meeting Abstract. 10.1016/j.annonc.2020.08.1589. 2020
Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
Calvo, V; (...); Pulla, MP
Meeting Abstract. 10.1016/j.annonc.2020.08.1555. 2020
FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.
Alcoriza-Balaguer MI; (...); Lahoz A
Article. 10.1093/bib/bbad064. 2023
Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)
Calvo, V.; (...); Provencio, M.
Meeting Abstract. 2021
Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
Edelman, MJ; (...); Saunders, A
Meeting Abstract. 10.1016/S1556-0864(18)30363-0. 2018
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
Pulla, MP; (...); Casado, MDI
Meeting Abstract. 2018
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemoradiation in stage III NSCLC. SLCG 10/02.
Provencio-Pulla, Mariano; (...); Isla, Dolores
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e20521. 2018
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 2023
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023
First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
Andric, Z. G.; (...); Ciardiello, F.
Meeting Abstract. 2021
First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is...
Juan, O, Yousaf, N, Popat, S
Editorial Material. 10.1016/j.clon.2016.09.007. 2017
First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Baclin, Firas; (...); Reck, Martin
Meeting Abstract. 2024
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Reck, Martin; (...); John, Tom
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Paz-Ares, L.; (...); Carbone, D. P.
Meeting Abstract. 2021
First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA
Reinmuth, N.; (...); John, T.
Meeting Abstract. 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares, Luis; (...); Reck, Martin
Article. 10.1016/S1470-2045(20)30641-0. 2021
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready, Neal E.; (...); Paz-Ares, Luis
Article. 10.1136/jitc-2022-006127. 2023
First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
Carbone, D.; (...); Lu, S.
Meeting Abstract. 2021
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Paz-Ares, Luis G.; (...); Carbone, David P.
Article. 10.1016/j.jtho.2022.10.014. 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; (...); John T
Article. 10.1016/j.esmoop.2021.100273. 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck, Martin; (...); Carbone, David P.
Article. 10.1016/j.ejca.2023.01.015. 2023
Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
Reck, Martin; (...); Paz-Ares, Luis G.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M; (...); Paz-Ares LG
Article. 10.1016/j.ejca.2024.114296. 2024
Follicular lymphoma: clinical and mollecular characteristics of histologic transformation
Garcia, MM; (...); Pulla, MP
Meeting Abstract. 2017
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; (...); Reck M
Article. 10.1136/jitc-2023-008189. 2024
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)
Le, Xiuning; (...); Wang, Jie
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Le, X.; (...); Wang, J.
Meeting Abstract. 2024
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.
Ghiringhelli, Francois; (...); Basse, Linda
Meeting Abstract. 2022
Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
Pros, E; (...); Sanchez-Cespedes, M
Meeting Abstract. 10.1016/j.jtho.2019.08.878. 2019
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; (...); Sanchez-Cespedes M
Article. 10.1016/j.annonc.2019.09.001. 2020
Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
Lopez Castro, R.; (...); Ponce Aix, S.
Meeting Abstract. 2023
Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience.
Girones, R; (...); Juan-Vidal, O
Article. 10.1111/ecc.12950. 2018
Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
Felip, E.; (...); Duruisseaux, M.
Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM
Article. 10.1016/j.ejca.2020.10.002. 2020
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations
Suay, Guillermo; (...); Lahoz, Agustin
Review. 10.1016/j.canlet.2024.217317. 2024
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients
Escoin-Perez C, Blasco S, Juan-Vidal O
Review. 10.1016/j.lungcan.2020.03.026. 2020
Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.; (...); Lorente, D.
Meeting Abstract. 2018
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Provencio M; (...); Calvo V
Article. 10.1016/j.lungcan.2023.107323. 2023
Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial
Guckenberger, M; (...); Stahel, RA
Meeting Abstract. 10.1016/j.annonc.2020.08.1731. 2020
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/cancers15061705. 2023
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
Provencio, M; (...); GOTEL Spanish Lymphoma Oncology Gr
Article. 10.1371/journal.pone.0177204. 2017
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Zugazagoitia, J; (...); Manzano, A
Letter. 10.1183/13993003.02431-2017. 2018
Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
Pardo-Sanchez, JM; (...); Farras, R
Article. 10.3390/cancers13122980. 2021
Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
Rodriguez, LPA; (...); Bunn, P
Meeting Abstract. 2019
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Mok, Tony S. K.; (...); Barlesi, Fabrice
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.
Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis
Article. 10.1158/1078-0432.CCR-22-0588. 2022
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
Merino, LD; (...); Dominguez, AR
Meeting Abstract. 2020
LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics
Alcoriza-Balaguer, MI; (...); Lahoz, A
Article. 10.1021/acs.analchem.8b03409. 2019
Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2021
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; (...); de Sevilla AF
Article. 10.1007/s00277-020-04056-9. 2020
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
De Castro, J; (...); Isla, D
Article. 10.1007/s12094-016-1527-8. 2017
Long-Term Survival of Phase II of Full-Dose Oral Vinorelbine Combined with Cisplatin Et Radiotherapy in Locally Advanced NSCLC
Juan, O; (...); Hernandez, AS
Meeting Abstract. 10.1016/j.jtho.2016.11.1159. 2017
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melian, M; (...); Juan, O
Article. 10.1111/1759-7714.12873. 2018
Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07
Isla, D; (...); Garrido, P
Article. 10.21873/anticanres.11273. 2016
Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).
Calvo, V; (...); Provencio, M
Meeting Abstract. 2021
Lung cancer symptoms at diagnosis: results of a nationwide registry study.
Ruano-Raviña A; (...); Cerezo S
Article. 10.1136/esmoopen-2020-001021. 2020
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, P; (...); Felip, E
Article. 10.1002/cam4.4135. 2021
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Lopez, PG; (...); Calvo, JP
Meeting Abstract. 2018
LungBEAM: A Prospective Multicenter Trial to Monitor EGFR Mutations Using BEAMing Technology in Stage IV NSCLC Patients
Garrido, P; (...); Palacios, J
Meeting Abstract. 10.1016/j.jtho.2017.09.584. 2017
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Remon, J; (...); Reguart, N
Article. 10.1016/j.lungcan.2020.06.034. 2020
Metabolic vulnerabilities of mesenchymal-like EGFR-mutant NSCLC cells with acquired resistance to tyrosine kinase inhibitors
Pulido, I; (...); Carretero, J
Meeting Abstract. 10.1158/1538-7445.AM2018-LB-099. 2018
Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
Angelats, L; (...); Carcereny, E
Meeting Abstract. 10.1016/j.jtho.2019.08.808. 2019
MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.
Ciardiello, Fortunato; (...); Galffy, Gabriella
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.TPS9123. 2019
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
Franco, F; (...); Provencio, M
Article. 10.3390/curroncol28020118. 2021
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Ponce, S; (...); Nadal, E
Review. 10.1016/j.critrevonc.2019.03.017. 2019
Mutational profile of primary breast diffuse large B-cell lymphoma
Franco, F; (...); Sanchez-Beato, M
Article. 10.18632/oncotarget.21986. 2017
nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Morgensztern D; (...); Ong TJ
Article. 10.3389/fonc.2020.569715. 2021
Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
Spigel, D; (...); Thomas, M
Meeting Abstract. 10.1016/j.jtho.2019.08.604. 2019
nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
Spigel, DR; (...); Thomas, M
Meeting Abstract. 2018
nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm
Gridelli, C; (...); Jotte, R
Meeting Abstract. 2017
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.
Thomas, M; (...); Gridelli, C
Article. 10.2147/LCTT.S138570. 2017
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; (...); ABOUND.sqm Investigators
Article. 10.1016/j.cllc.2020.09.007. 2021
NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients
Rodriguez-Abreu, D; (...); Majem, M
Meeting Abstract. 10.1016/j.jtho.2018.08.1467. 2018
NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Nadal, E.; (...); Bruna, J.
Meeting Abstract. 2022
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2020
Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Reck, M; (...); Paz-Ares, LG
Meeting Abstract. 2021
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
Reinmuth, Niels; (...); Bondarenko, Igor
Article. 10.1158/1078-0432.CCR-24-0013. 2024
Oligometastatic non-small-cell lung cancer (NSCLC) and unresectable primary tumor: Updated retrospective analysis of safety and efficacy of the radical treatment for the primary tumor and the metastases
Marin, S.; (...); Llombar Cussac, A.
Meeting Abstract. 10.1016/S1556-0864(16)30254-4. 2016
Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.
Mesía R; (...); Pujol E
Article. 10.1007/s11864-019-0686-6. 2019
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D; (...); Provencio M
Article. 10.1016/j.lungcan.2018.11.041. 2019
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G; (...); Mitsudomi, T
Article. 10.1016/S1470-2045(16)30508-3. 2016
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; (...); Calvo V
Article. 10.1186/s12885-021-07922-5. 2021
OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX
Terrasa, J; (...); Provencio, M
Meeting Abstract. 2021
Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.
Perez, Concepcion; (...); Mira, Jose J.
Article. 10.3390/jpm11020102. 2021
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J; (...); Besse B
Article. 10.1016/j.cllc.2021.07.008. 2021
Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I
Ponce Aix, S.; (...); Paz-Ares, L.
Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul
Article. 10.1111/bjh.18941. 2023
Perspectives in oligometastatic brain lesions in non-small cell lung cancer (NSCLC)
Salvador Coloma, C.; (...); Juan, O.
Meeting Abstract. 10.1016/S1556-0864(16)30255-6. 2016
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
Gonzalez-Cao, M; (...); Rosell, R
Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.2501. 2019
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E; (...); Bruna J
Article. 10.1200/JCO.22.02561. 2023
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn, Myung-Ju; (...); Paz-Ares, Luis
Article. 10.1080/14796694.2024.2402152. 2024
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients
Martin, P; (...); Garde-Noguera, J
Meeting Abstract. 10.1016/j.jtho.2016.11.1880. 2017
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Garde-Noguera, J; (...); Juan-Vidal, O
Article. 10.1007/s12094-017-1829-5. 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients (vol 20, pg 1072, 2018)
Garde-Noguera, J; (...); Juan-Vidal, O
Correction. 10.1007/s12094-018-1916-2. 2018
Preliminarily results of the Oncohabitats Study: A multicentre validation of overall survival (OS) estimation of patients with glioblastoma (GBM) using vascular biomarkers
Alvarez-Torres, MD; (...); Garcia-Gomez, JM
Meeting Abstract. 10.1158/1538-7445.AM2019-4258. 2019
Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study
Bondarenko, I; (...); Reinmuth, N
Meeting Abstract. 2018
Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Felip, E.; (...); Ganti, A.
Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Vidal, OJJ; (...); Palanca, S
Meeting Abstract. 2019
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
Franco Pérez F; (...); Provencio M
Article. 10.1016/j.clml.2016.09.004. 2017
Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
Juan, O; (...); Codina, JG
Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
Antonio Mendez, Juan; (...); Juan Vidal, Oscar
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Gutierrez, L; (...); Provencio, M
Article. 10.1186/s12885-021-08713-8. 2021
Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group
Provencio, M; (...); Spanish Lymphoma Oncology Grp
Article. 10.1002/cncr.30795. 2017
PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
Spigel, DR; (...); Reck, M
Meeting Abstract. 2021
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa, Lucia; (...); Sanchez-Beato, Margarita
Article. 10.1038/s41598-020-80376-0. 2021
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP
Article. 10.3389/fonc.2021.695038. 2021
Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+
Talbot, D; (...); Ong, TJ
Meeting Abstract. 10.1016/j.jtho.2018.08.649. 2018
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Aix, SP; (...); Morgensztern, D
Article. 10.2217/fon-2019-0796. 2020
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman, Martin J.; (...); DISTINCT Study Investigators
Article. 10.1016/j.lungcan.2022.03.003. 2022
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Peters, S; (...); EMPHASIS-lung Collaborative Group
Article. 10.1016/j.jtho.2016.12.017. 2017
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results
Reck, M; (...); Nakagawa, K
Article. 10.1016/j.cllc.2017.11.003. 2018
Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study
Carpeno, JD; (...); Rojo, F
Meeting Abstract. 2019
Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Perea, J.; (...); Gaudens, P. Capdevila
Meeting Abstract. 2023
Recommendations of GeSIDA/PETHEMA on the Diagnosis and Treatment of Lymphomas in Patients Infected by the Human Immunodeficiency Virus
Miralles, P; (...); Santasusana, JMR
Editorial Material. 10.1016/j.medcli.2017.11.037. 2018
RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares, Luis; (...); Bunn, Paul A.
Article. 10.1002/cncr.34123. 2022
RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
Ponce, S; (...); Bunn, PA
Meeting Abstract. 10.1016/j.annonc.2020.08.1554. 2020
RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
Paz-Ares, L; (...); Bunn, P
Meeting Abstract. 2021
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
Spigel, DR; (...); Bunn, P
Meeting Abstract. 2020
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
Paz-Ares, Luis G.; (...); Bunn, Paul
Meeting Abstract. 2020
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer-Preliminary findings from part 1 dose-defining phase.
Paz-Ares, Luis G.; (...); Bunn, Paul A.
Meeting Abstract. 2019
RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
Conde, E.; (...); Lopez-Rios, F.
Meeting Abstract. 2021
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde, Esther; (...); Lopez-Rios, Fernando
Article. 10.1016/j.jtocrr.2024.100653. 2024
RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
Hernandez, S.; (...); Conde, E.
Meeting Abstract. 2022
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Article. 10.1200/JCO.24.00733. 2024
Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01
Garassino, M. C.; (...); Paz-Ares, L. G.
Meeting Abstract. 2024
Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
Juan, O; (...); Girones, R
Meeting Abstract. 10.1016/j.jtho.2016.11.1255. 2017
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
Spigel DR; (...); Reck M
Article. 10.1016/j.annonc.2021.01.071. 2021
Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2022.02.062. 2022
SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma
Provencio Pulla M; (...); Rueda Domínguez A
Article. 10.1007/s12094-015-1437-1. 2015
SEOM clinical guidelines for the treatment of Hodgkin's lymphoma
Rueda Domínguez A; (...); Provencio Pulla M
Article. 10.1007/s12094-015-1429-1. 2015
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
Majem M; (...); Provencio M
Article. 10.1007/s12094-018-1978-1. 2019
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Garcia-Campelo, Rosario; (...); Domine, Manuel
Article. 10.1007/s12094-023-03216-3. 2023
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).
Guma, Josep; (...); Provencio, Mariano
Article. 10.1007/s12094-023-03206-5. 2023
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio, Mariano; (...); Cobo, Manuel
Article. 10.21037/tlcr-21-504. 2022
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach.
Vera, Ruth; (...); del Alba, Aranzazu Gonzalez
Article. 10.1007/s12094-023-03112-w. 2023
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Suay, Guillermo; (...); Juan-Vidal, Oscar
Review. 10.3390/cancers15184433. 2023
Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)
Carcereny Costa, E.; (...); Provencio Pulla, M.
Meeting Abstract. 10.1016/j.annonc.2020.08.1547. 2020
Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Castro, RL; (...); Provencio, M
Meeting Abstract. 2019
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Peressini M; (...); Zugazagoitia J
Article. 10.1158/1078-0432.CCR-24-0104. 2024
Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma
Franco, F; (...); Pulla, MP
Meeting Abstract. 2017
Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
Mielgo-Rubio X; (...); Couñago F
Editorial Material. 10.5306/wjco.v11.i12.983. 2020
Survival in young adults diagnosed with follicular lymphoma
Calvo, V; (...); Rueda, A
Letter. 10.1093/annonc/mdv627. 2016
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
Provencio-Pulla, Mariano; (...); Romero, Atocha
Meeting Abstract. 2023
Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Blanco, R; (...); Vidal, OJJ
Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ; (...); Paz-Ares L
Article. 10.1056/NEJMoa2307980. 2023
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/ijms23158526. 2022
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
Edelman, M; (...); Deng, CQ
Meeting Abstract. 2020
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gomez Rueda, Ana; (...); Garrido, Pilar
Article. 10.1007/s12094-024-03404-9. 2024
Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.
Franco, F; (...); Provencio, M
Meeting Abstract. 2021
Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients
Wilhelmina Bracht, Jillian; (...); Rosell, Rafael
Meeting Abstract. 10.1158/1538-7445.AM2020-929. 2020
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Mendez, M; (...); Provencio, M
Article. 10.1002/hon.2601. 2019
Translating cancer epigenomics into the clinic: focus on lung cancer
Mari-Alexandre, J; (...); Sandoval, J
Review. 10.1016/j.trsl.2017.05.008. 2017
Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer
Palanca-Ballester, Cora; (...); Sandoval, Juan
Article. 10.1186/s13148-022-01334-3. 2022
Tratamiento con afatinib en primera linea EGFR M+. Resultados segun subtipo de mutacion.
Article. 10.1016/S0025-7753(16)30258-5. 2016
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
Juan, O, Popat, S
Review. 10.1177/1758834016687262. 2017
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
Garon, EB; (...); Nakagawa, K
Article. 10.1016/j.cllc.2016.05.023. 2017
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.
Isla D; (...); Juan-Vidal O
Article. 10.1007/s12094-020-02518-0. 2021
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
Gonzalez-Rincon, J; (...); Sanchez-Beato, M
Article. 10.1371/journal.pone.0212813. 2019
Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases.
Nadal, Ernest; (...); Bruna, Jordi
Meeting Abstract. 2022
Use of Geriatric Assessment (GA) in Clinical Practice for Stage IV Non-Small Cell Lung Cancer (NSCLC). The GIDO Experience
Girones, R; (...); Juan, O
Meeting Abstract. 2017
Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report.
Simarro J; (...); Palanca S
Article. 10.3390/diagnostics12051266. 2022